Management of non-small-cell lung cancer: Recent developments

The Lancet

Volumn 382, Issue 9893, 2013, Pages 709-719

  Reck, Martin ^a   Heigener, David F ^a   Mok, Tony ^c   Soria, Jean Charles ^d,e   Rabe, Klaus F ^a,b  

^a GERMAN CENTER FOR LUNG RESEARCH   (Germany)

^b UNIVERSITY OF KIEL   (Germany)

^c CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^d INSTITUT GUSTAVE ROUSSY   (France)

^e University Paris South   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ANAPLASTIC LYMPHOMA KINASE; BEVACIZUMAB; CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; GEFITINIB; GEMCITABINE; MICROTUBULE ASSOCIATED PROTEIN; NAVELBINE; PACLITAXEL; PEMETREXED; TEGAFUR;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; DNA MODIFICATION; GENE MUTATION; GENE REARRANGEMENT; HUMAN; LUNG NON SMALL CELL CANCER; MULTIMODALITY CANCER THERAPY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; STEREOTACTIC BODY RADIATION THERAPY; SURGICAL APPROACH;

EID: 84883013481     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(13)61502-0     Document Type: Review

References (101)

1. A Jemal, F Bray, MM Center, J Ferlay, E Ward, D Forman Global cancer statistics CA Cancer J Clin 61 2011 69 90
2. R Lozano, M Naghavi, K Foreman et al. Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010 Lancet 380 2012 2095 2128
3. SS Devesa, F Bray, AP Vizcaino, DM Parkin International lung cancer trends by histologic type: male:female differences diminishing and adenocarcinoma rates rising Int J Cancer 117 2005 294 299
4. D Morgensztern, SH Ng, F Gao, R Govindan Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database survey J Thorac Oncol 5 2010 29 33
5. JH Schiller, D Harrington, CP Belani the Eastern Cooperative Oncology Group Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer N Engl J Med 346 2002 92 98
6. DN Carney Lung cancer - time to move on from chemotherapy N Engl J Med 346 2002 126 128
7. A Sandler, R Gray, MC Perry et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer N Engl J Med 355 2006 2542 2550
8. GV Scagliotti, P Parikh, J von Pawel et al. Phase III study comparing cisplatin plus gemcitabine with cisplatin plus pemetrexed in chemotherapy-naive patients with advanced-stage non-small-cell lung cancer J Clin Oncol 26 2008 3543 3551
9. TS Mok, YL Wu, S Thongprasert et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma N Engl J Med 361 2009 947 957
10. R Rosell, E Carcereny, R Gervais the Spanish Lung Cancer Group in collaboration with Groupe Français de Pneumo-Cancérologie and Associazione Italiana Oncologia Toracica Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial Lancet Oncol 13 2012 239 246
11. EL Kwak, YJ Bang, DR Camidge et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer N Engl J Med 363 2010 1693 1703
12. P Goldstraw, J Crowley, K Chansky the International Association for the Study of Lung Cancer International Staging Committee the Participating Institutions The IASLC Lung Cancer Staging Project: proposals for the revision of the TNM stage groupings in the forthcoming (seventh) edition of the TNM Classification of malignant tumours J Thorac Oncol 2 2007 706 714
13. WD Travis, E Brambilla, M Noguchi et al. International Association for the Study of Lung Cancer/American Thoracic Society/European Respiratory Society international multidisciplinary classification of lung adenocarcinoma J Thorac Oncol 6 2011 244 285
14. FA Shepherd, J Dancey, R Ramlau et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy J Clin Oncol 18 2000 2095 2103
15. N Hanna, FA Shepherd, FV Fossella et al. Randomized phase III trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy J Clin Oncol 22 2004 1589 1597
16. FA Shepherd, J Rodrigues Pereira, T Ciuleanu the National Cancer Institute of Canada Clinical Trials Group Erlotinib in previously treated non-small-cell lung cancer N Engl J Med 353 2005 123 132
17. JS Temel, JA Greer, A Muzikansky et al. Early palliative care for patients with metastatic non-small-cell lung cancer N Engl J Med 363 2010 733 742
18. JT Annema, JP van Meerbeeck, RC Rintoul et al. Mediastinoscopy vs endosonography for mediastinal nodal staging of lung cancer: a randomized trial JAMA 304 2010 2245 2252
19. B Fischer, U Lassen, J Mortensen et al. Preoperative staging of lung cancer with combined PET-CT N Engl J Med 361 2009 32 39
20. JP Pignon, H Tribodet, GV Scagliotti the LACE Collaborative Group Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group J Clin Oncol 26 2008 3552 3559
21. W Sause, P Kolesar, S Taylor IV et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Cooperative Oncology Group, and Southwest Oncology Group Chest 117 2000 358 364
22. JP van Meerbeeck, GW Kramer, PE Van Schil the European Organisation for Research and Treatment of Cancer-Lung Cancer Group Randomized controlled trial of resection versus radiotherapy after induction chemotherapy in stage IIIA-N2 non-small-cell lung cancer J Natl Cancer Inst 99 2007 442 450
23. KS Albain, RS Swann, VW Rusch et al. Radiotherapy plus chemotherapy with or without surgical resection for stage III non-small-cell lung cancer: a phase III randomised controlled trial Lancet 374 2009 379 386
24. R Rami-Porta, JJ Crowley, P Goldstraw The revised TNM staging system for lung cancer Ann Thorac Cardiovasc Surg 15 2009 4 9
25. J Cuaron, M Dunphy, A Rimner Role of FDG-PET scans in staging, response assessment, and follow-up care for non-small cell lung cancer Front Oncol 2 2012 208
26. FC Detterbeck, MA Jantz, M Wallace, J Vansteenkiste, GA Silvestri the American College of Chest Physicians Invasive mediastinal staging of lung cancer: ACCP evidence-based clinical practice guidelines (2nd edn) Chest 132 suppl 2007 202S 220S
27. JT Annema, MI Versteegh, M Veseliç, P Voigt, KF Rabe Endoscopic ultrasound-guided fine-needle aspiration in the diagnosis and staging of lung cancer and its impact on surgical staging J Clin Oncol 23 2005 8357 8361
28. KG Tournoy, F De Ryck, LR Vanwalleghem et al. Endoscopic ultrasound reduces surgical mediastinal staging in lung cancer: a randomized trial Am J Respir Crit Care Med 177 2008 531 535
29. JT Annema, MI Versteegh, M Veseliç et al. Endoscopic ultrasound added to mediastinoscopy for preoperative staging of patients with lung cancer JAMA 294 2005 931 936
30. RC Rintoul, KG Tournoy, H El Daly et al. EBUS-TBNA for the clarification of PET positive intra-thoracic lymph nodes - an international multi-centre experience J Thorac Oncol 4 2009 44 48
31. KG Tournoy, JT Annema, M Krasnik, FJ Herth, JP van Meerbeeck Endoscopic and endobronchial ultrasonography according to the proposed lymph node map definition in the seventh edition of the tumor, node, metastasis classification for lung cancer J Thorac Oncol 4 2009 1576 1584
32. FJ Herth, R Eberhardt, M Krasnik, A Ernst Endobronchial ultrasound-guided transbronchial needle aspiration of lymph nodes in the radiologically and positron emission tomography-normal mediastinum in patients with lung cancer Chest 133 2008 887 891
33. FJ Herth, KF Rabe, S Gasparini, JT Annema Transbronchial and transoesophageal (ultrasound-guided) needle aspirations for the analysis of mediastinal lesions Eur Respir J 28 2006 1264 1275
34. MS Bhutani, RH Hawes, BJ Hoffman A comparison of the accuracy of echo features during endoscopic ultrasound (EUS) and EUS-guided fine-needle aspiration for diagnosis of malignant lymph node invasion Gastrointest Endosc 45 1997 474 479
35. P Ulivi, M Romagnoli, E Chiadini et al. Assessment of EGFR and K-ras mutations in fixed and fresh specimens from transesophageal ultrasound-guided fine needle aspiration in non-small cell lung cancer patients Int J Oncol 41 2012 147 152
36. R van Eijk, J Licht, M Schrumpf et al. Rapid KRAS, EGFR, BRAF and PIK3CA mutation analysis of fine needle aspirates from non-small-cell lung cancer using allele-specific qPCR PLoS One 6 2011 e17791
37. R Zhang, K Ying, L Shi, L Zhang, L Zhou Combined endobronchial and endoscopic ultrasound-guided fine needle aspiration for mediastinal lymph node staging of lung cancer: a meta-analysis Eur J Cancer 49 2013 1860 1867
38. J Varlotto, A Fakiris, J Flickinger et al. Matched-pair and propensity score comparisons of outcomes of patients with clinical stage I non-small cell lung cancer treated with resection or stereotactic radiosurgery Cancer 2013 10.1002/cncr.28100 published online April 19.
39. CG Robinson, TA DeWees, IM El Naqa et al. Patterns of failure after stereotactic body radiation therapy or lobar resection for clinical stage I non-small-cell lung cancer J Thorac Oncol 8 2013 192 201
40. H Dienemann, H Hoffmann [VATS lobectomy in stage I lung cancer: standard or experimental procedure] Zentralbl Chir 137 2012 228 233 (in German).
41. D Lardinois, P De Leyn, P Van Schil et al. ESTS guidelines for intraoperative lymph node staging in non-small cell lung cancer Eur J Cardiothorac Surg 30 2006 787 792
42. N Martini, MS Bains, ME Burt et al. Incidence of local recurrence and second primary tumors in resected stage I lung cancer J Thorac Cardiovasc Surg 109 1995 120 129
43. R Arriagada, A Auperin, S Burdett the NSCLC Meta-analyses Collaborative Group Adjuvant chemotherapy, with or without postoperative radiotherapy, in operable non-small-cell lung cancer: two meta-analyses of individual patient data Lancet 375 2010 1267 1277
44. GM Strauss, JE Herndon 2nd, MA Maddaus et al. Adjuvant paclitaxel plus carboplatin compared with observation in stage IB non-small-cell lung cancer: CALGB 9633 with the Cancer and Leukemia Group B, Radiation Therapy Oncology Group, and North Central Cancer Treatment Group Study Groups J Clin Oncol 26 2008 5043 5051
45. C Hamada, F Tanaka, M Ohta et al. Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer J Clin Oncol 23 2005 4999 5006
46. C Hamada, M Tsuboi, M Ohta et al. Effect of postoperative adjuvant chemotherapy with tegafur-uracil on survival in patients with stage IA non-small cell lung cancer: an exploratory analysis from a meta-analysis of six randomized controlled trials J Thorac Oncol 4 2009 1511 1516
47. WA Song, NK Zhou, W Wang et al. Survival benefit of neoadjuvant chemotherapy in non-small cell lung cancer: an updated meta-analysis of 13 randomized control trials J Thorac Oncol 5 2010 510 516
48. E Lim, G Harris, A Patel, I Adachi, L Edmonds, F Song Preoperative versus postoperative chemotherapy in patients with resectable non-small cell lung cancer: systematic review and indirect comparison meta-analysis of randomized trials J Thorac Oncol 4 2009 1380 1388
49. PORT Meta-analysis Trialists Group Postoperative radiotherapy for non-small cell lung cancer Cochrane Database Syst Rev 2 2005 CD002142
50. BE Lally, D Zelterman, JM Colasanto, BG Haffty, FC Detterbeck, LD Wilson Postoperative radiotherapy for stage II or III non-small-cell lung cancer using the surveillance, epidemiology, and end results database J Clin Oncol 24 2006 2998 3006
51. C Le Péchoux Role of postoperative radiotherapy in resected non-small cell lung cancer: a reassessment based on new data Oncologist 16 2011 672 681
52. YY Janjigian, BJ Park, MF Zakowski et al. Impact on disease-free survival of adjuvant erlotinib or gefitinib in patients with resected lung adenocarcinomas that harbor EGFR mutations J Thorac Oncol 6 2011 569 575
53. G Goss, I Lorimer, AS Tsao, CJ O'Callaghan, K Ding A phase III randomized, double-blind, placebo-controlled trial of the epidermal growth factor receptor inhibitor gefitinib in completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): NCIC CTG BR.19 J Clin Oncol 28 18S 2012 abstract LBA7005.
54. H Tada, K Takeda, K Nakagawa Vinorelbine plus cisplatin versus gefitinib in resected non-small cell lung cancer harboring activating EGFR mutation (WJOG6410L) J Clin Oncol 30 suppl 2012 abstract TPS7110.
55. KA Olaussen, A Dunant, P Fouret the IALT Bio Investigators DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy N Engl J Med 355 2006 983 991
56. M Cobo, D Isla, B Massuti et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer J Clin Oncol 25 2007 2747 2754
57. L Friboulet, KA Olaussen, JP Pignon et al. ERCC1 isoform expression and DNA repair in non-small-cell lung cancer N Engl J Med 368 2013 1101 1110
58. B Besse, KA Olaussen, JC Soria ERCC1 and RRM1: ready for prime time? J Clin Oncol 31 2013 1050 1060
59. B Besse, F Andre, JC Soria What can be done for patients with NSCLC without druggable targets? Lancet Oncol 14 2013 191 192
60. A Aupérin, C Le Péchoux, JP Pignon the Meta-Analysis of Cisplatin/carboplatin based Concomitant Chemotherapy in non-small cell Lung Cancer (MAC3-LC) Group Concomitant radio-chemotherapy based on platin compounds in patients with locally advanced non-small cell lung cancer (NSCLC): a meta-analysis of individual data from 1764 patients Ann Oncol 17 2006 473 483
61. A Aupérin, C Le Péchoux, E Rolland et al. Meta-analysis of concomitant versus sequential radiochemotherapy in locally advanced non-small-cell lung cancer J Clin Oncol 28 2010 2181 2190
62. C Schinkel, C Mueller, J Reinmiedl, H Fuerst Morbidity and survival after bronchoplastic surgery for non-small-cell lung cancer J Cardiovasc Surg (Torino) 41 2000 637 640
63. A Gómez-Caro, S Garcia, N Reguart et al. Determining the appropriate sleeve lobectomy versus pneumonectomy ratio in central non-small cell lung cancer patients: an audit of an aggressive policy of pneumonectomy avoidance Eur J Cardiothorac Surg 39 2011 352 359
64. NSCLC Meta-Analyses Collaborative Group Chemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trials J Clin Oncol 26 2008 4617 4625
65. M Reck, J von Pawel, P Zatloukal et al. Phase III trial of cisplatin plus gemcitabine with either placebo or bevacizumab as first-line therapy for nonsquamous non-small-cell lung cancer: AVAiL J Clin Oncol 27 2009 1227 1234
66. A Ardizzoni, L Boni, M Tiseo the CISCA (CISplatin versus CArboplatin) Meta-analysis Group Cisplatin- versus carboplatin-based chemotherapy in first-line treatment of advanced non-small-cell lung cancer: an individual patient data meta-analysis J Natl Cancer Inst 99 2007 847 857
67. E Quoix, J Oster, V Westeel, E Pichon Weekly paclitaxel combined with monthly carboplatin versus single-agent therapy in patients age 70 to 89: IFCT-0501 randomized phase III study in advanced non-small cell lung cancer (NSCLC) J Clin Oncol 28 18S 2010 abstract 2.
68. R Lilenbaum, M Zukin, J Rodrigues Pereira, CH Barrios A randomized phase III trial of single-agent pemetrexed (P) versus carboplatin and pemetrexed (CP) in patients with advanced non-small cell lung cancer (NSCLC) and performance status (PS) of 2 J Clin Oncol 30 suppl 2012 abstract 7506.
69. T Ciuleanu, T Brodowicz, C Zielinski et al. Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: a randomised, double-blind, phase 3 study Lancet 374 2009 1432 1440
70. F Cappuzzo, T Ciuleanu, L Stelmakh the SATURN investigators Erlotinib as maintenance treatment in advanced non-small-cell lung cancer: a multicentre, randomised, placebo-controlled phase 3 study Lancet Oncol 11 2010 521 529
71. L Paz-Ares, F de Marinis, M Dediu et al. Maintenance therapy with pemetrexed plus best supportive care versus placebo plus best supportive care after induction therapy with pemetrexed plus cisplatin for advanced non-squamous non-small-cell lung cancer (PARAMOUNT): a double-blind, phase 3, randomised controlled trial Lancet Oncol 13 2012 247 255
72. F Barlesi, J de Castro, V Dvornichenko et al. Final efficacy outcomes for patients (pts) with advanced non-squamous non-small cell lung cancer (nsNSCLC) randomised to continuation maintenance (mtc) with bevacizumab (bev) or bev + pemetrexed (pem) after first line (1L) bev-cisplatin (cs)-pem treatment (tx) Eur J Cancer 47 suppl 2 2011 16 (abstract 34LBA).
73. MJ Edelman, T Le Chevalier, JC Soria Maintenance therapy and advanced non-small-cell lung cancer: a skeptic's view J Thorac Oncol 7 2012 1331 1336
74. CJ Langer, B Besse, A Gualberto, E Brambilla, JC Soria The evolving role of histology in the management of advanced non-small-cell lung cancer J Clin Oncol 28 2010 5311 5320
75. N Ferrara, KJ Hillan, HP Gerber, W Novotny Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer Nat Rev Drug Discov 3 2004 391 400
76. JC Soria, A Mauguen, M Reck the meta-analysis of bevacizumab in advanced NSCLC collaborative group Systematic review and meta-analysis of randomised, phase II/III trials adding bevacizumab to platinum-based chemotherapy as first-line treatment in patients with advanced non-small-cell lung cancer Ann Oncol 24 2013 20 30
77. P Ceppi, M Volante, S Saviozzi et al. Squamous cell carcinoma of the lung compared with other histotypes shows higher messenger RNA and protein levels for thymidylate synthase Cancer 107 2006 1589 1596
78. G Scagliotti, S Novello, J von Pawel et al. Phase III study of carboplatin and paclitaxel alone or with sorafenib in advanced non-small-cell lung cancer J Clin Oncol 28 2010 1835 1842
79. TS Mok Personalized medicine in lung cancer: what we need to know Nat Rev Clin Oncol 8 2011 661 668
80. TJ Lynch, DW Bell, R Sordella et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139
81. JG Paez, PA Jänne, JC Lee et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500
82. M Soda, YL Choi, M Enomoto et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer Nature 448 2007 561 566
83. FR Hirsch, PA Jänne, WE Eberhardt et al. Epidermal growth factor receptor inhibition in lung cancer: status 2012 J Thorac Oncol 8 2013 373 384
84. T Mok, JJ Yang, KC Lam Treating patients with EGFR-sensitizing mutations: first line or second line - is there a difference? J Clin Oncol 31 2013 1081 1088
85. JH Paik, G Choe, H Kim et al. Screening of anaplastic lymphoma kinase rearrangement by immunohistochemistry in non-small cell lung cancer: correlation with fluorescence in situ hybridization J Thorac Oncol 6 2011 466 472
86. DR Camidge, YJ Bang, EL Kwak et al. Activity and safety of crizotinib in patients with ALK-positive non-small-cell lung cancer: updated results from a phase 1 study Lancet Oncol 13 2012 1011 1019
87. AT Shaw, DW Kim, K Nakagawa et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer N Engl J Med 368 2013 2385 2394
88. E Felip, C Gridelli, P Baas, R Rosell, R Stahel the Panel Members Metastatic non-small-cell lung cancer: consensus on pathology and molecular tests, first-line, second-line, and third-line therapy: 1st ESMO Consensus Conference in Lung Cancer; Lugano 2010 Ann Oncol 22 2011 1507 1519
89. D Jackman, W Pao, GJ Riely et al. Clinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancer J Clin Oncol 28 2010 357 360
90. AT Shaw, JA Engelman ALK in lung cancer: past, present, and future J Clin Oncol 31 2013 1105 1111
91. MV Karamouzis, PA Konstantinopoulos, AG Papavassiliou Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors Lancet Oncol 10 2009 709 717
92. RC Doebele, AB Pilling, DL Aisner et al. Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small-cell lung cancer Clin Cancer Res 18 2012 1472 1482
93. Tartour E, Zitvogel L. Lung cancer: potential target for immunotherapy. Lancet Respir Med (in press).
94. L Decoster, I Wauters, JF Vansteenkiste Vaccination therapy for non-small-cell lung cancer: review of agents in phase III development Ann Oncol 23 2012 1387 1393
95. SL Topalian, FS Hodi, JR Brahmer et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer N Engl J Med 366 2012 2443 2454
96. JR Brahmer, SS Tykodi, LQ Chow et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer N Engl J Med 366 2012 2455 2465
97. M Reck, I Bondarenko, A Luft et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial Ann Oncol 24 2013 75 83
98. TJ Lynch, I Bondarenko, A Luft et al. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study J Clin Oncol 30 2012 2046 2054
99. R Govindan, L Ding, M Griffith et al. Genomic landscape of non-small cell lung cancer in smokers and never-smokers Cell 150 2012 1121 1134
100. M Maemondo, A Inoue, K Kobayashi et al. Gefitinib or chemotherapy for non-small-cell lung cancer with mutated EGFR N Engl J Med 362 2010 2380 2388
101. Patel J, Socinski MA, Garon EB, et al. A randomized, open-label, phase 3, superiority study of pemetrexed (Pem)+carboplatin (Cb)+bevacizumab (B) followed by maintenance Pem+B versus paclitaxel (Pac)+Cb+B followed by maintenance B in patients (pts) with stage IIIB or IV non-squamous nonsmall cell lung cancer (NS-NSCLC). 2012 Chicago Multidisciplinary Symposium in Thoracic Oncology; Chicago, IL, USA; 6-8 Sept, 2012; abstract LBPL1.